Survodutide has shown promising results for reducing HbA1c levels in phase 1 and 2 clinical trials presented at the American Diabetes Association's Scientific Sessions, in Orlando, Florida.
The analysis covered results from three clinical trials: a phase 2 study in patients with only obesity (NCT04667377), a phase 2 trial in patients with type 2 diabetes (NCT04153929), and a phase 1 trial in a similar cohort without diabetes (NCT03591718).
Key findings indicated that high doses of survodutide considerably improved insulin sensitivity, as evidenced by reductions in HOMA-IR scores compared to placebo across the studies. In the obesity only trial, the HOMA-IR score decreased by -1.1 with survodutide versus -0.2 with placebo at week 46.
Aurvodutide consistently elevated HOMA-β scores, suggesting enhanced pancreatic islet function. In the type 2 diabetes trial, the mean percentage change from baseline to end of treatment in HOMA-β was significantly higher with survodutide (88%) compared to placebo (18%).
Other glucose-related biomarkers showed favorable changes with survodutide treatment. In the obesity study, there were notable differences in fasting plasma glucose, insulin, non-fasting plasma glucose, adiponectin, glucagon, and c-peptide levels between survodutide and placebo groups.
Disclosures
- E.I. Ekinci holds advisory roles and has received research support from multiple pharmaceutical companies, including Lilly Diabetes, Abbott, Eli Lilly and Company, Novo Nordisk, Boehringer-Ingelheim, Endogenex, Versanis, and AstraZeneca.
- J. Martinez, A.M. Hennige, and C. Schölch are employees of Boehringer-Ingelheim.
